Blueprint Medicines (BPMC) Receives a Buy from Jefferies

Jefferies analyst Eun Yang maintained a Buy rating on Blueprint Medicines (BPMCResearch Report) yesterday and set a price target of $78.00. The company’s shares closed yesterday at $61.17.

Yang covers the Healthcare sector, focusing on stocks such as United Therapeutics, Blueprint Medicines, and Verve Therapeutics. According to TipRanks, Yang has an average return of 5.0% and a 48.51% success rate on recommended stocks.

In addition to Jefferies, Blueprint Medicines also received a Buy from Stifel Nicolaus’s Bradley Canino in a report issued today. However, on the same day, SVB Securities maintained a Hold rating on Blueprint Medicines (NASDAQ: BPMC).

See Insiders’ Hot Stocks on TipRanks >>

Based on Blueprint Medicines’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $36.55 million and a GAAP net loss of $159.71 million. In comparison, last year the company earned a revenue of $27.3 million and had a GAAP net loss of $108.44 million

Based on the recent corporate insider activity of 66 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BPMC in relation to earlier this year. Most recently, in May 2022, Nicholas Lydon, a Director at BPMC bought 10,909.00 shares for a total of $213,052.77.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Blueprint Medicines Corp. is a precision therapy company. It focuses on medicines to improve the lives of patients with genomically defined cancers, rare diseases and cancer immunotherapy. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.

Read More on BPMC:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More